Opinion|Videos|March 4, 2025
Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC
Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
- How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
5